Different Clinicopathological Characteristics in Indonesian Colorectal Patients with NRAS Mutations and HER2 Over-Expression

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2023 Apr 28

PMID 37116161

Authors

Kiki Lukman

Ade Tan Reza

Lisa Y Hasibuan

Yunia Sribudiani

Birgitta Maria Dewayani

Reno Rudiman

Etis Primastari

Prapanca Nugraha

Affiliations

Soon will be listed here.

Abstract

Objective: This study aims to assess the association of subject characteristics and NRAS mutations with HER2 expression in CRC.

Methods: This research is a cross-sectional study. The research subjects in this study were colorectal cancer patients in the Digestive Surgery division at Dr. Hasan Sadikin Hospital. There were 58 study subjects. Examination of NRAS mutations was carried out by Polymerase Chain Reaction (PCR) from fresh tumour tissue obtained from surgery or colonoscopy. Meanwhile, HER2 examination used the Immunohistochemistry (IHC) method of paraffin blocks for anatomical pathology examination of the same patients.

Result: HER2 overexpression was found in 6/58 (10.3%) patients with CRC, and from 8 subjects with NRAS mutations, only 1 subject (1.7%) showed overexpression of HER2. Univariate analysis of HER2 expression showed no significant associations to age, sex, histologic feature, tumor location, and NRAS mutations. A significant association was found between HER2 expression and stage of the CRC with p=0.001.

Conclusion: There is no association between NRAS mutations and HER2 overexpression in colorectal cancer patients.

References

Wang Y, Velho S, Vakiani E, Peng S, Bass A, Chu G . Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression. Cancer Discov. 2013; 3(3):294-307. PMC: 3595397. DOI: 10.1158/2159-8290.CD-12-0198. View

Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D . NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol. 2010; 19(3):157-63. PMC: 2929976. DOI: 10.1097/PDM.0b013e3181c93fd1. View

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C . A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2012; 1(6):508-23. DOI: 10.1158/2159-8290.CD-11-0109. View

Iqbal N, Iqbal N . Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014; 2014:852748. PMC: 4170925. DOI: 10.1155/2014/852748. View

Levi M, Prayogi G, Sastranagara F, Sudianto E, Widjajahakim G, Gani W . Clinicopathological Associations of K-RAS and N-RAS Mutations in Indonesian Colorectal Cancer Cohort. J Gastrointest Cancer. 2017; 49(2):124-131. DOI: 10.1007/s12029-016-9901-x. View

Xi Y, Xu P . Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021; 14(10):101174. PMC: 8273208. DOI: 10.1016/j.tranon.2021.101174. View

Valentini A, Cavalcanti E, Di Maggio M, Caruso M . RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine. Appl Immunohistochem Mol Morphol. 2018; 26(8):539-544. PMC: 6135466. DOI: 10.1097/PAI.0000000000000475. View

Prior I, Hood F, Hartley J . The Frequency of Ras Mutations in Cancer. Cancer Res. 2020; 80(14):2969-2974. PMC: 7367715. DOI: 10.1158/0008-5472.CAN-19-3682. View

Ross J, Fakih M, Ali S, Elvin J, Schrock A, Suh J . Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018; 124(7):1358-1373. PMC: 5900732. DOI: 10.1002/cncr.31125. View

10.

Sanchez-Ibarra H, Jiang X, Gallegos-Gonzalez E, Cavazos-Gonzalez A, Chen Y, Morcos F . KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study. PLoS One. 2020; 15(7):e0235490. PMC: 7337295. DOI: 10.1371/journal.pone.0235490. View

11.

Gong S, Xu D, Zhu J, Zou F, Peng R . Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells. Cell Physiol Biochem. 2018; 47(2):680-693. DOI: 10.1159/000490022. View

12.

Porru M, Pompili L, Caruso C, Biroccio A, Leonetti C . Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. J Exp Clin Cancer Res. 2018; 37(1):57. PMC: 5850913. DOI: 10.1186/s13046-018-0719-1. View

13.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G . Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11(8):753-62. DOI: 10.1016/S1470-2045(10)70130-3. View

14.

Abdul Razzaq E, Venkatachalam T, Bajbouj K, Rahmani M, Mahdami A, Rawat S . HER2 overexpression is a putative diagnostic and prognostic biomarker for late-stage colorectal cancer in North African patients. Libyan J Med. 2021; 16(1):1955462. PMC: 8330780. DOI: 10.1080/19932820.2021.1955462. View

15.

Sullivan K, Kozuch P . Impact of KRAS Mutations on Management of Colorectal Carcinoma. Patholog Res Int. 2011; 2011:219309. PMC: 3062096. DOI: 10.4061/2011/219309. View

16.

Lee W, Park Y, Lee J, Baek J, Lee T, Ha S . Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. Cancer Med. 2014; 3(3):674-80. PMC: 4101759. DOI: 10.1002/cam4.228. View

17.

Seo A, Kwak Y, Kim D, Kang S, Choe G, Kim W . HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One. 2014; 9(5):e98528. PMC: 4039475. DOI: 10.1371/journal.pone.0098528. View

18.

Meriggi F, Vermi W, Bertocchi P, Zaniboni A . The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies. Rev Recent Clin Trials. 2014; 9(1):8-12. DOI: 10.2174/1568026614666140423121525. View

19.

Jafari M, Laraqui A, Baba W, Benmokhtar S, El Zaitouni S, Ait Ali A . Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa. BMC Cancer. 2022; 22(1):1142. PMC: 9639273. DOI: 10.1186/s12885-022-10235-w. View

20.

. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-7. PMC: 3401966. DOI: 10.1038/nature11252. View